not a bad share !
buffett and woodford have sold out though , i am reducing a bit .
![Smile :)](./images/smilies/icon_e_smile.gif)
Thanks to smokey01,bungeejumper,stockton,Anonymous,bruncher, for Donating to support the site
FredBloggs wrote:What do the Fools think of my objective of being paid handsomely while waiting for the share price to pick up some lost ground?
I sold my pharma shares a while back ( I had considered them buy and hold forever shares) after watching a Horizon programme on future developments, one of which included gene therapy for terminal cancer which was curative. Its early days, but the unlocking of the human genome has huge implications for the way we look at curing disease. Big pharma has millions (billions?) collectively invested in drug development programmes that may have no future. I think they have a tough time ahead.
ADrunkenMarcus wrote:
I intend to sell my remaining GSK holding and reinvest the proceeds in one of my other shares with a stronger balance sheet and, I think, better longer term prospects for dividend growth (Kone) - at the cost of a lower initial dividend yield.
Itsallaguess wrote:I've got to say that I don't sell what I consider to be core-holdings lightly, but Glaxo is the one share in my HYP (ignoring the political-risk holdings such as the utilities, that I'm biding my time on currently) that I feel is flashing a warning light at me, similar to the one I really should have taken notice of earlier with regards to my Carillion sale after the last profit warning.
GeoffF100 wrote:Share Centre appears to have some good stuff:
https://www.share.com/find-investments/ ... &csi=10042
If you look at Financials - Fundamentals you will find Cash Flow From Operating Activities which is £6.198 billion in the last FY. Note f says that dividend payments are included in this figure.
Share Centre's conclusion is "We continue with our Buy recommendation for investors seeking income and willing to accept a lower level of risk."
GeoffF100 wrote:If you look at Financials - Fundamentals you will find Cash Flow From Operating Activities which is £6.198 billion in the last FY. Note f says that dividend payments are included in this figure.
Return to “Pharmaceuticals & Bio-Pharma”
Users browsing this forum: No registered users and 2 guests